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PREDICTION OF NOVEL ANTI-EBOLA VIRUS COMPOUNDS 
UTILIZING ARTIFICIAL NEURAL NETWORK (ANN) 
 
Ronald Bartzatt*
 
 
Chemistry Department, Durham Science Center, University of Nebraska at Omaha 6001 
Dodge Street, Omaha Nebraska, USA. 
 
ABSTRACT 
Artificial Neural Network (ANN) analysis is shown to predict the 
molecular properties of new anti-EBOLA compounds following 
training/learning by use of 60 previously known and studied drugs. 
Following training/learning by applying properties of 60 known drugs 
the TIBERIUS ANN system can efficiently predict the molecular 
properties of comparable new drugs. Molecular weight (MW) is an 
important and dominant property of perspective drugs considered for 
clinical trials. TIBERIUS ANN was able to predict comparable values 
of MW for drugs following training cycles. One-way ANOVA, F and 
T tests indicate that actual and predicted MW have the same means 
(P=.99). Passing-Bablok regression showed that ANN predicted MW 
are comparable to actual MW. The coefficient of variation indicated actually less variation in 
predicted MW as opposed to actual MW. A plot of actual MW values versus ANN predicted 
MW values, produced a line having no departure from linearity (P=.82), and a 95% ellipses 
having 55 drugs therein. TIBERIUS ANN allows investigators to input separate property 
values to predict suitable outcome based on the 60 known drugs. ANN prediction of 
pharmaceutical properties of new drugs is shown to be efficient and accurate when based on a 
known set of drugs for training/learning cycle. 
 
KEYWORDS: Ebola, Artificial Neural Network, Viral Hemorrhagic Fever. 
  
INTRODUCTION 
The typical organization of neural networks are in layers. These layers are composed of 
interconnected nodes which contain an activation function. An activation function of a 
specific node will define the output of that node for the given input (or set of inputs).
[1]
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Respective patterns are presented to the network through the input layer, followed by 
communication to one or more of hidden layers, in which the actual processing is 
accomplished through a system of weighted connections.
[1,2]
 These hidden layers are linked 
to an output layer from which the answer is ejected.  
 
Artificial neural networks (ANN) are successfully being used for drug design and drug 
discovery process. For this purpose there are various types of ANN:
[2]
 1) Multilayered 
perceptron/backpropagation networks; 2) Kohenen neural networks; 3) Counter propagation 
networks; 4) Bayesian neural networks; 5) Recurrent neural network. ANN analysis has the 
capacity to resolve nonlinear relationships, making them advantageous compared to other 
statistical techniques incorporating pattern analysis.
[2]
 For this study, a particular feature 
advantageous to ANN is their ability to model complex relationships among various 
physicochemical properties (i.e. molecular properties), in addition to, mapping correlations of 
several variables of the particular chemical structures.
[2]
  
 
Artificial neural networks can form a mathematical model for the way a drug is transported to 
a target cell or target tissue.
[3]
 This is accomplished by ANN through the solving of nonlinear 
problems of multivariate and multi-response type systems, which is the scenario for drug 
transport.
[3]
 ANN analysis can be used to model complex relationships among actual causal 
variable inputs and resulting outputs.
[3]
 ANN has been used for the prediction of in vitro 
dissolution profiles of various matrix-controlled release formulations.
[4]
 Attempts to 
pharmacokinetic modeling pursue the prediction of concentration time profiles of a drug 
while it is in the body after drug administration. This is the study of the absorption, 
distribution, metabolism, and elimination (ADME) processes of the drug.
[5]
 The relationship 
between drug concentration and its positive/negative response can be studied via the 
simulation and modeling techniques provided by ANN.
[5]
  
 
This study will utilize the molecular properties of 60 known effective and tested inhibitors of 
EBOLA virus.
[6,7]
 By applying pattern recognition power of ANN, followed by various 
numerical analysis methods, the efficiency and usefulness of ANN for prediction of new ever 
very important anti-EBOLA compounds is accomplished. The power of drug development is 
expanded and made more efficacious by use of ANN capabilities. 
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MATERIALS AND METHODS 
Molecular Properties and Molecular Modeling 
Numerical values of molecular properties (i.e. Log P, polar surface are, molecular weight) for 
all compounds were determined through heuristic calculation through Molinspiration 
Chemical Properties Service (Molinspiration Cheminformatics, Nova ulica 61, SK-900 26 
Slovensky Grob, Slovak Republic). Elucidation of molecular structural components was 
accomplished utilizing ACD ChemSketch Modeling v. 12.01 (Advanced Chemistry 
Development, 110 Yonge Street, Toronto Ontario, M5C 1T4 Canada, 
http://www.molinspiration.com/services/search.html). Molinspiration Cheminformatics 
(http://www.molinspiration.com/cgibin/properties) determined molecular properties of Log P, 
polar surface area (Angstroms
2
), molecular weight, number of atoms, molecular volume 
(Angstroms
3
), number of nitrogen, oxygen, amine groups, and hydroxyl groups.  
 
Statistical Analysis and Prediction 
Prediction of numerical values for various molecular properties was accomplished by 
utilizing TIBERIUS v. 7.0.7 (http://www.tiberius.biz/, copyright 2001, Copyright © Tiberius 
Data Mining, and Copyright © 1999-2007 NeuSolutions). TIBERIUS trial version can be 
obtained at http://www.tiberius.biz/download.html. Statistical analysis of numerical data to 
include molecular properties of the compounds in this study was accomplished by Microsoft 
EXCEL v.14.0.6112.5000 (EXCEL Professional plus 2010). Other statistical tests such as 
ANOVA analysis, F and T test, coefficient of variation, 95% ellipses, and Kruskal-Wallis test 
was accomplished utilizing PAST version 2.06 (copyright Oyvind Hammer, D.A.T. Harper, 
2011). Numerical outliers were identified, where stated, by using Grubb’s analysis for 
outliers online GraphPad (http://www.graphpad.com/quickcalcs/). Passing-Bablok regression 
was accomplished utilizing Method Validator (www.multiqc.com). Box plots were 
accomplished utilizing Smith’s Statistical Package v. 2.5 (copyright © 1995-2001, Gary 
Smith). 
 
RESULTS AND DISCUSSION 
Ebola virus disease, also known as Ebola haemorrhagic fever, is a severe and often fatal 
illness in humans. Direct contact with various body fluids is considered a major risk factor for 
contracting and induction of this illness.
[6]
 Further evidence of contracting the disease is 
presence of blood abnormalities, such as decreased platelets.
[6]
 Other organs involved include 
renal, cardiac, lung, gastrointestinal, neurological and hepatic tissue acting as indicators of 
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the virus presence.
[6]
 A high fever and hemorrhagic manifestations (hemorrhagic 
conjunctivitis, bleeding ulcerations of mouth and lips, gingival bleeding, hematemesis, ear 
bleeding, hematuria) are most often observed in patients.
[6]
 
 
Infection with this virus is characterized by a massive production of pro-inflammatory 
cytokines, a severe host immunosuppression that accompanies a rapid viremia, with 
manifestation of a fulminant hemorrhagic fever.
[7]
 The apparent high virulence accompanying 
rapid progression of infection, contributes to the high fatality rate.
[7]
 For this study, utilizing 
TIBERIUS ANN based prediction, the molecular properties of 60 compounds that are known 
to inhibit the proliferation of viral EBOLA have been recognized and compiled.
[6,7]
 These 60 
compounds have molecular structures that are presented in Fig 1 and Fig 2. These 60 
compounds originate from more than 50 chemical classes of compounds and have been 
studied because of their antiviral activity.
[6]
 Among these 60 compounds are counted 
approved drugs, antiviral agents in clinical trials, various lead compounds, various 
exploratory chemical probes and others from screening hits.
[7]
 Discussed and examined in 
terms of their molecular properties in previous studies,
[6,7]
 this work will endeavor to 
demonstrate that ANN is suitable for prediction of new anti-EBOLA compounds when 
utilizing the molecular properties in Table 1 for “training” the ANN.  
 
All 60 compounds presented in Fig 1, Fig 2, and Table 1 have molecular weight less than 600 
daltons, which is considered to be “small molecules” in the fields of pharmacology and 
molecular biology.
[8, 9]
 Most drugs are small molecules.
[8, 9]
 The molecular weight cut-off of 
900 Daltons is a necessary condition for favorable bioavailability in terms of transcellular 
transport.
[8]
 Small molecule drugs over larger molecules is the ease and efficiency of oral 
administration.
[10]
 Larger molecules generally requiring injection or other parenteral 
administration (intramuscular, subcutaneous, and intravenous).
[10]
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Figure. 1: Compounds 1 to 35 that inhibit growth of EBOLA virus. 
 
 
Figure. 2: Compounds 36 to 60 that inhibit EBOLA virus. 
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Table. 1. Molecular Properties of 60 Known Anti-EBOLA Compounds. 
Compound Log P 
Polar Surface Area 
(Angstroms2) 
Number of 
Atoms 
Molecular 
Weight 
Oxygen 
Nitrogen Atoms 
Number of OH and 
NHn Groups 
Rule of 5 
Violations 
Rotatable 
Bonds 
Volume 
(Angstroms3) 
1 -0.98 88.85 11 157.1 5 3 0 1 119.06 
2 -2.24 140.31 19 265.27 8 7 1 2 225.72 
3 -1.13 130.32 19 265.27 8 5 0 2 226.35 
4 -1.14 130.32 19 263.26 8 5 0 2 220.13 
5 4.31 114.83 41 620.46 10 0 1 8 492.1 
6 1.88 97.03 24 342.44 7 2 0 11 335.67 
7 -1.37 169.93 25 357.41 10 7 1 12 330.98 
8 -1.93 128.33 26 369.42 9 3 0 8 338.96 
9 0.16 166.27 30 426.56 10 7 1 15 422.72 
10 1.93 131.69 40 543.64 9 3 1 14 508.68 
11 4.95 138.1 39 537.62 11 4 2 10 490.72 
12 2.45 116.06 23 321.38 9 2 0 9 304.06 
13 2.67 116.06 23 321.38 9 2 0 9 303.7 
14 4.64 29.54 28 387.61 3 0 0 6 405.62 
15 4.16 6.48 21 280.42 2 0 0 4 287.31 
16 5.04 88.18 42 573.73 8 1 2 11 543.75 
17 5.78 12.47 27 377.92 2 0 1 7 356.31 
18 6.06 12.47 29 405.97 2 0 1 9 389.91 
19 6.58 29.54 28 448.38 3 0 1 12 380.93 
20 4.55 64.9 36 532.47 8 0 1 8 462.72 
21 3.64 42.68 23 307.35 4 0 0 2 278.13 
22 4.48 70.08 33 466.6 6 1 0 11 428.61 
23 5.07 48.91 25 330.36 3 2 1 3 292.05 
24 5.22 53.6 29 404.51 4 2 1 6 360.35 
25 2.27 90.89 20 270.24 5 3 0 1 224.05 
26 3.93 56.28 22 315.76 5 1 0 4 268.16 
27 4.99 97.63 39 529.53 8 2 1 7 446.63 
28 3.89 86.28 37 493.62 8 2 0 7 461.44 
29 6.11 162.62 58 817.07 12 4 3 11 786.22 
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30 8.31 42.68 31 645.32 4 0 2 11 437.04 
31 7.94 88.85 39 556.77 7 1 2 18 533.46 
32 4.55 63.97 33 454.61 6 0 0 13 454.3 
33 5.72 144.52 38 516.55 8 5 2 6 457.44 
34 2.79 84.09 21 301.33 6 2 0 4 246.9 
35 1.1 83.11 29 399.44 7 1 0 5 364.15 
36 1.33 93.38 26 375.41 6 4 0 9 338.63 
37 2.35 104.46 30 428.61 7 4 0 10 436.32 
38 2.72 116.49 31 443.63 8 5 0 10 448.73 
39 3.13 83.98 25 352.42 6 2 0 4 305.39 
40 4.84 24.73 23 320.29 2 0 0 3 260.99 
41 3.58 58.37 22 413.26 5 1 0 7 301.35 
42 3.16 12.47 21 281.4 2 0 0 4 283.8 
43 3.48 20.31 22 309.43 2 0 0 0 284.23 
44 8.93 60.68 34 460.66 3 3 1 6 466.57 
45 0.47 137.67 26 346.39 7 7 1 4 306.64 
46 3.77 63.05 32 445.59 6 1 0 5 405.9 
47 5.38 48.38 24 341.84 4 2 1 5 308.75 
48 5.96 53.34 34 452.6 4 0 1 9 440.81 
49 5 28.16 22 319.88 3 1 1 8 313.12 
50 7.67 57.17 32 466.41 4 3 1 6 409.58 
51 4.72 56.31 34 458.65 6 2 0 10 458.26 
52 6.6 78.78 35 577.43 8 1 2 7 436.37 
53 4.8 114.69 44 620.87 8 3 1 7 630.37 
54 -2.18 206.6 41 584.66 12 8 3 4 520.54 
55 2.11 166.29 43 599.73 11 5 2 7 570.06 
56 1.97 267.04 58 822.94 16 8 3 7 741.93 
57 4.11 95.86 35 479.62 6 3 0 2 460.9 
58 3.52 84.86 29 421.56 6 2 0 1 391.39 
59 2.89 112.93 37 507.63 7 3 1 4 479.11 
60 3.84 92.9 37 517.61 8 2 1 7 453.35 
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The TIBERIUS ANN has been structured and is ready to be trained. Training process 
includes assigning initial weights for the inputs, which in this study is set to be all equal 
(setting to 1.00 each). This training is set to a learning pace of 0.70 and to run over a desired 
number of “EPOCHS”, with the error minimized. There are two approaches to training - 
supervised and unsupervised.
[1, 2]
 Supervised training requires a mechanism of providing the 
network with a manual grading of network performance or by providing desired outputs 
along with the inputs. Unsupervised training pushes the network to make sense of the inputs 
without outside influence. The vast majority of networks utilize supervised training.
[1, 2]
  
 
Prediction of molecular weights for novel anti-EBOLA compounds due to ease of ANN 
application and the importance of molecular weight in determining the efficacy of potential 
drug compounds. Various screening tools for identifying potential drugs will include 
molecular weight as important criteria for selection. The very popular “Rule of 5” has a 
criteria of molar mass must be less than 500 Daltons.
[11]
 An extension of the Rule of 5 is the 
Ghose criteria (CMC Rule) that requires a molecular weight of 180 to 500 Daltons.
[12]
 The 
QED criteria includes molecular weight in its own parameters.
[13]
 The BDDCS criteria, along 
with the ECCCS criteria consider a molecular weight of 400 Daltons to be important.
[14]
 This 
in addition to the finding that more than 80% of all traded drugs have molecular weight 
below 450 Daltons.
[11]
 Therefore, molecular weight is an excellent choice for utilizing ANN 
to screen for novel drug properties following training with the properties in Table 1, for 60 
proven EBOLA inhibitors.  
 
The flow chart of TIBERIUS ANN compilation of data to “Results and Query Table” is 
presented in Fig 3. The steps in Fig 3 were applied to this study and should be effective in 
general application of thisback-propagating ANN methodology. 
 
Presented in Fig 4 is a standard spreadsheet for input of data/information into TIBERIUS 
ANN, which allows the selection of desired variables (descriptors) for appropriate training 
and selection of output variables (molecular weight for this study). Note that the first row is 
appropriate indicators of the molecular properties (see Table 1) (i.e. PSA= polar surface area, 
natoms = number of atoms, MW = molecular weight, nON = number of oxygen nitrogen, 
nrotb = number of rotatable bonds, volume = molecular volume). These are selected for input 
or for output. 
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Figure. 3: Flow chart of TIBERIUS ANN application for implementing known 
molecular properties for training, followed by prediction of new properties of potential 
drugs. 
 
 
Figure. 4: Input EXCEL spread sheet having all pertinent variables (descriptors) for 
ANN training and analysis. 
www.wjpr.net                                Vol 7, Issue 13, 2018.  
 
25 
Bartzatt.                                                                World Journal of Pharmaceutical Research 
Following selection of input variables and out variable (molecular weight in this study), the 
model is initiated into training utilizing input variables from spreadsheet of molecular 
properties shown in Fig 4, these derived from the compilation in Table 1. Following training, 
the model will identify variables having highest importance for generation of results. The 
highest importance level is 1.000, followed by various levels of numerical values less than 
1.00. For this study the outcome of relative importance for variable and relative importance, 
respectively: Log P (1.000), number of oxygen & nitrogen (0.994), polar surface area (0.459), 
number of –OH & nHNn (0.050), and number of rotatable bonds (0.002).  
 
 
Figure. 5: Results Table and Query Table where new molecular property values can be 
entered into “current val” row to determine best fit molecular weight (MW) based on 
ANN analysis of 60 proven anti-EBOLA virus compounds (see inset arrow). 
 
In the “Results and Query” window the final predicted molecular weight values are compared 
to the actual molecular weight values of the training set, and with the numerical values of 
error calculated (Fig 5). The actual molecular weight values and predicted molecular weight 
values are compiled in Table 2 for comparison and statistical analysis. The actual molecular 
weights of compounds 1 to 60, having structures presented in Fig 1 and Fig 2, and nine 
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molecular properties in Table 1, with ANN predicted molecular weights are shown in Table 
2. The following statistical evaluation of the predicted MW to actual MW will show that 
ANN is effective, efficient, and possessing high level of accuracy. 
 
Table. 2. Comparison of Actual values of MW to ANN Predicted Values of MW. 
Compound 
Actual 
MW 
Predicted 
MW 
Compound 
Actual 
MW 
Predicted 
MW 
Compound 
Actual 
MW 
Predicted 
MW 
1 157.1 210.11 21 307.35 337.77 41 413.26 374.92 
2 265.27 264.12 22 466.6 451.52 42 281.4 237.47 
3 265.27 311.95 23 330.36 357.00 43 309.43 253.71 
4 263.26 311.57 24 404.51 397.16 44 460.66 510.94 
5 620.46 602.18 25 270.24 336.10 45 346.39 339.69 
6 342.44 398.25 26 315.76 383.45 46 445.59 411.98 
7 357.41 389.78 27 529.53 540.84 47 341.84 397.20 
8 369.42 327.38 28 493.62 487.71 48 452.6 443.22 
9 426.56 447.31 29 817.07 744.10 49 319.88 346.18 
10 543.64 483.47 30 645.32 524.22 50 466.41 486.47 
11 537.62 647.74 31 556.77 635.49 51 458.65 438.54 
12 321.38 490.98 32 454.61 457.68 52 577.43 591.37 
13 321.38 499.37 33 516.55 590.93 53 620.87 542.72 
14 387.61 339.63 34 301.33 386.72 54 584.66 434.03 
15 280.42 269.72 35 399.44 356.92 55 599.73 556.72 
16 573.73 544.80 36 375.41 329.45 56 822.94 762.80 
17 377.92 340.18 37 428.61 407.24 57 479.62 439.16 
18 405.97 352.71 38 443.63 452.59 58 421.56 412.57 
19 448.38 419.16 39 352.42 399.59 59 507.63 438.31 
20 532.47 508.09 40 320.29 312.71 60 517.61 492.32 
 
Carrying out the One-way ANOVA evaluation of actual and predicted MW, indicated that the 
overall means for the two groups are equal (P=.99).
[15]
 Applying the F and T test, the 
outcome shows that actual and predicted MW values have the same mean (P=.99) and the 
two population variances are equal (P=.36).
[15]
 The Pearson r correlation between the two sets 
of values, actual and predicted, shows very strong positive relationship (r = 0.8879). The 
paired t-test and Wilcoxon indicated that the sets of MW values have the same median 
(P=.69) and same median (P=.13).
[15]
 The Kolmogorov-Smirnov test indicates the two sets of 
MW values are taken from populations having equal distributions (P=.72). In addition, the 
Kruskal-Wallis test indicates the two sets have equal medians (P=.99).  
 
Both sets of MW values were examined for numerical outliers within the training MW (actual 
MW) and predicted MW. The Grubbs' test, also called the ESD method (extreme studentized 
deviate), determines whether one of the values in either list of MW values is a signficant 
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outlier from the rest.
[15]
 The Grubb’s test did not find any outliers within the 60 values of 
actual MW or the predicted MW values.  
 
The coefficient of variation (CV) is a measure of relative variability. It is the ratio of the 
standard deviation to the mean (average).
[15]
 CV is useful for comparing results from two 
different tests that have differing values. The higher the numerical values of CV, the higher 
the variation. The actual MW of 60 anti-EBOLA compounds showed a CV of 30.15%, 
whereas the predicted MW values showed CV of 26.78%. Therefore, the variation in MW of 
the ANN predicted values is less than the variation in actual MW for these 60 compounds. 
 
The simple two-way plot of actual MW versus predicted MW is shown in Fig 6. Here is seen 
the regression line through the origin intercept (solid line) with equation (y = 0.9828x) with 
Pearson r = 0.8581. Interpretation of this model means that for every one point increase in 
actual MW values there is a 0.99 (nearly 1.00) for predicted MW, or in other words a linear 
slope of 1.00. This is accomplished by ANN prediction of MW, noting the slope of the origin 
intercepting regression line is 0.9828 (see Fig 6). The non-origin intercept regression model 
(dotted line) with equation (y = 0.7885x + 91.52) with Pearson r =0.8879. This line is also 
shown to have 34 runs by the runs test (test to determined test whether the line fit by linear 
regression deviates systematically your data), indicating no significant departure from 
linearity (P=.82).
[15] 
In both cases, the Pearson r-values indicate a very strong positive 
relationship. 
 
Further interpretation of the effectiveness and accuracy of ANN prediction of MW for anti-
EBOLA compounds can be achieved by applying Passing-Bablok regression analysis.
[16]
 
Passing–Bablok regression is a statistical method for non-parametric regression analysis 
suitable for method comparison studies.
[16]
 The outcome are interpreted so that if 0 is in the 
confidence interval for the y-axis intercept, and 1 is in the confidence interval of the slope, 
the two methods are comparable within the investigated range. If 0 is not in the confidence 
interval of the y-axis intercept then there is a systematic difference, however, if 1 is not in the 
confidence interval of.  
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Figure. 6: Linearity of actual values molecular weights (x-axis) to predicted values 
molecular weights (y-axis). Pearson r correlation of line with regression through origin 
is 0.8561 (y = 0.9828x), slope equal to 0.9828 which is > 98% of 1.000. Pearson r 
correlation for line with non-zero y-axis intercept line is 0.8879 (y=0.7885x + 91.52). 
 
The slope then there is a proportional difference between the two methods.
[16]
 Passing-Bablok 
plot of actual MW versus predicted MW (see Fig 7) shows that 1 is in the confidence interval 
of the slope and 0 is in the confidence interval of the y-axis intercept. Therefore, the actual 
and predicted MW values are systematically the same and there is no proportional difference 
between the two sets of MW values. 
 
Box plots are drawn for groups of data to enable the study of the distributional characteristics 
of more than one group. They are excellent for detecting and illustrating location and 
variation changes between different groups of data.
[15]
 Any outliers are identified as 
individual points and the line in the box represents the median. The actual MW values and 
predicted MW are presented in the form of Box plots in Fig 8. Clearly, the median lines 
indicated are essentially coincident with predicted values of MW contained within the box for 
actual values of MW. This finding corroborates the outcome of coefficient of variation as 
well as Passing-Bablok regression analysis. 
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Figure. 7: Passing-Bablok plot comparing actual molecular weights to predicted 
molecular weight obtained from TIBERIUS ANN analysis. 
 
An additional graphical approach for visualizing the similarity of actual MW and ANN 
predicted MW is through 95% confidence ellipses, presented in Fig 9. Essentially a 95% 
ellipses can be applied if you were to replicate your sampling from the underlying 
distribution many times and each time calculate a confidence ellipse, then 95% of the ellipses 
so constructed would contain the underlying mean and demonstrate consistency of numerical 
values.
[15]
  
 
The two-way plot of actual MW values (independent variable) versus predicted MW values 
by TIBERIUS ANN (dependent variable) is shown in Fig 9. The position of each compound 
within the 95% ellipses is indicated by using the numbering system in Table 1. Note that the 
plotted points for compounds 13, 12, 29, 11, and 56 are the only drugs that fall outside the 
95% ellipses. This finding further corroborates the overall effectiveness of ANN prediction of 
MW for anti-EBOLA compounds by modeling with TIBERIUS system. 
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Figure. 8: Box plots for comparing actual molecular weights to predicted molecular 
weights obtained from ANN analysis of 60 known anti-EBOLA compounds.  
 
 
Figure. 9: 95% ellipses comparing actual molecular weights to predicted molecular 
weights.  
  
The Query Table (see inset arrow for Fig 5) allows the investigator to input differing values 
of critical properties, and then determine the corresponding MW. This is a powerful 
capability of TIBERIUS ANN that allows direct prediction of the expected structural 
molecular properties of potential drugs from the 60 training known anti-EBOLA inhibitors 
(see Fig 1, Fig 2, and Table 1). Examples shown in Table 3, show that the change of critical 
descriptors Log P, polar surface area, number of oxygen & nitrogen, number of –OH and –
NHn, and rotatable bonds, will result in the predicted molecular weight values. This 
capability allows investigators to build potential drug candidates based on 60 known anti-
EBOLA compounds and with rational predicted MW, PSA, etc. 
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Table. 3. Example of Property Prediction from Query Table. 
Log P 
Polar 
Surface Area 
(Angstroms
2
) 
Number of oxygen 
& Nitrogen Atoms 
Number of 
-OH and –NHn 
Number of 
Rotatable 
Bonds 
Predicted Molecular 
Weight (grams/mole) 
-0.98 88.85 5 3 1 210.1189 
-0.98 88.85 10 3 1 345.3661 
-0.98 88.85 10 5 1 330.0396 
3.5 180 10 5 1 590.6643 
3.5 180 10 5 12 600.8023 
3.5 30 10 5 12 512.2134 
3.5 90 5 5 12 376.9663 
3.5 90 5 2 12 399.9559 
2.5 88.85 4 3 1 315.8251 
 
 
Figure. 10: Neighbor joining cluster analysis. Drugs have closest proximity are most 
similar. 
 
The interrelationships of all 60 anti-EBOLA compounds presented in Fig 1, Fig 2, and Table 
1 can be visualized by neighbor-joining cluster analysis, which is presented in Fig 10. 
Neighbor joining cluster analysis is a bottom-up (agglomerative) clustering method for the 
creation of trees to find the members of the various branches of the tree that have the highest 
similarity to each other.
[17]
 In the neighbor-joining method, a modified distance matrix is 
constructed in which the separation between each pair of nodes is adjusted based on their 
average divergence from all other nodes.
[17]
 In this manner, the distance of members of the 
tree can be optimized and be based on their numerical similarities in the various molecular 
properties utilized in this study. Neighbor cluster analysis in Fig 10, produced super nodes A 
and B, and whereas, node A is further divided into two sub-branches at node C. Compounds 
found in each of these major branches are determined to be most similar to each other based 
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on molecular properties (see Table 1), with further discrimination into sub-nodes where 
compounds closest to each other are most similar. Presumably, this will allow expectations 
for pharmacokinetic activity and which compound would have activity. 
 
The application of TIBERIUS ANN for training with 60 known anti-EBOLA compounds 
(see Fig 1 and Fig 2) allowed the prediction of molecular weights that were statistically the 
same as the original training set (see Table 1). Various statistical analysis proved the 
numerical efficiency of ANN prediction of molecular property. In addition, the TIBERIUS 
ANN system permits the investigator to input various numerical values for critical properties, 
followed by accurate prediction of the desired “output” variable (molecular weight for this 
study). Although applied in this study for the prediction of new properties of new anti-
EBOLA compounds, this same approach can be applied to other drugs that are clinically 
proven for the treatment of many other threatening diseases (i.e. malaria). The prediction, 
identification, and study of novel drugs for clinical application is an ever important endeavor 
within the field of medicinal chemistry. ANN is now shown to be a powerful tool for that 
endeavor. 
 
CONCLUSION 
Results of this study showed that TIBERIUS ANN can effectively predict important 
molecular properties of novel anti-EBOLA compounds following training utilizing properties 
of 60 known drugs that inhibit proliferation of EBOLA virus. Specifically demonstrated for 
values of molecular weight, TIBERIUS ANN can be utilized to achieve the same objective 
for any desired descriptor of new drugs. TIBERIUS allows the input of varying numerical 
values of any property placed into the “input” nodes, for consequential effect on “output” 
node (molecular weight for this study). Predicted MW values were shown to be statistically 
the same as actual MW of the training set by one-way ANOVA, F and T test. Comparison of 
actual and predicted molecular weight values were shown to be highly comparable with equal 
means by Passing-Bablok regression and one-way ANOVA, respectively. Box plots and 
coefficient of variation showed predicted and actual molecular weights to be comparable and 
effective. The use of ANN is a powerful tool for predicting properties of novel drug designs 
when effective training/learning data is administered to “input” nodes.  
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